Diageo share price dips as Fitch pulls ratings coverage and board news lands
20 January 2026
1 min read

Diageo share price dips as Fitch pulls ratings coverage and board news lands

London, 20 January 2026, 09:09 GMT — Regular session.

  • Diageo shares dipped in early London trading following a new move by Fitch on the company’s credit rating.
  • A board disclosure revealed that Diageo non-executive John Rishton is set to become chair at Imperial Brands later this year.
  • Traders are keeping an eye on a Kenya court schedule linked to Diageo’s planned sale of its EABL stake, as interim results approach next month.

Diageo shares (DGE.L) slipped roughly 0.4% in early Tuesday trading, valuing the maker of Guinness and Johnnie Walker at 1,618.5 pence. 1

The shift puts the spotlight on balance sheet and policy risks just as investors show little tolerance for surprises from global consumer firms. Credit news and tariff chatter are increasingly shaping the tape, rivaling traditional brand narratives.

Diageo slipped 1.84% on Monday, ending the day at £16.25 and trailing the wider FTSE 100 decline. According to MarketWatch, the shares remain roughly 37% off their 52-week peak. 2

On Monday, Fitch Ratings affirmed Diageo’s rating at ‘A-’ but assigned a negative outlook and withdrew some of its ratings for commercial reasons. The issuer default rating reflects a borrower’s capacity to repay debt, while the negative outlook suggests a potential downgrade. 3

Separately, Diageo announced that non-executive director John Rishton will take on the role of chair designate at Imperial Brands starting July 13, 2026, before stepping up as chair on Dec. 1. 4

Imperial Brands announced the appointment came after a planned succession, with senior independent director Sue Clark praising Rishton as “an exceptional candidate as Chair.” Rishton added he “look forward to working with the Board.” 5

The broader market drag remains in play. Spirits companies with significant U.S. sales took a hit Monday following President Donald Trump’s warning about potential new import tariffs targeting EU and UK goods. Diageo, Pernod Ricard, Rémy Cointreau, and Campari all saw their shares slip. 6

Investors are keeping an eye on the legal timeline. Reuters reported earlier this month that Kenya’s High Court has pushed a hearing on the case trying to block Diageo’s $2.3 billion sale of its EABL stake to Japan’s Asahi to Jan. 20. The court is expected to issue further directions then. EABL responded, “We welcome the court’s decision to allow the regulatory phases of this transaction to continue.” 7

That said, the situation can flip. A stricter court ruling in Kenya, tariffs shifting from talk to actual levies, or any hint that debt cuts falter could weigh on the shares—despite Tuesday’s modest move.

Diageo is set to release its interim results for the six months ending Dec. 31 on Feb. 25, per the company’s financial calendar. This report will probably influence the stock’s trajectory through March. 8

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Vodafone share price edges up after fresh buyback disclosure — here’s what traders watch next
Previous Story

Vodafone share price edges up after fresh buyback disclosure — here’s what traders watch next

IAG share price drops: what’s moving International Consolidated Airlines Group stock today
Next Story

IAG share price drops: what’s moving International Consolidated Airlines Group stock today

Go toTop